Health ministries in six Southern African nations are planning a mass rollout of the HIV-prevention drug lenacapavir starting this month [1].
The initiative targets the region hardest hit by the epidemic to curb transmission through a highly effective, long-acting medical intervention [3].
The rollout includes South Africa, Zambia, Eswatini, Zimbabwe, Lesotho, and Mozambique [1]. This coordinated effort aims to provide a scalable solution in areas where the virus remains a critical public health challenge. South Africa, in particular, carries the world's highest HIV burden [3].
Lenacapavir differs from traditional prevention methods due to its administration schedule. The drug is administered only twice a year [1]. This infrequent dosing may improve adherence compared to daily oral medications, which is a significant hurdle in large-scale prevention programs.
Clinical data indicates the drug provides more than 99% protection against HIV infection [1]. By reducing the frequency of clinic visits and the need for daily pills, health officials hope to reach more at-risk populations across the six participating countries [1].
The deployment comes as health ministries seek to modernize their response to the epidemic. The transition to a twice-yearly injectable represents a shift toward more sustainable, long-term prevention strategies in Southern Africa [1].
“The drug is administered only twice a year”
The shift from daily oral PrEP to a twice-yearly injection addresses the primary barrier to HIV prevention: patient adherence. By reducing the required touchpoints between patients and healthcare providers from 365 days to two, these nations can potentially lower the operational strain on their healthcare systems while increasing the total number of protected individuals in high-burden zones.
